Notable updates, news, or analysts actions from our trading lists followed by 'Our Take'. Iovance Biotherapeutics price target raised to $57 from $43 at Oppenheimer - $IOVA Oppenheimer analyst Mark Breidenbach raised the firm's price target on Iovance Biotherapeutics to $57 from $43 and reiterates an Outperform rating on the shares after meeting with management. Iovance is providing the FDA with a consolidated package of potency assay and assay validation data to make the FDA's review process as streamlined as possible, Breidenbach tells investors in a research note. The analyst continues to speculate that the issue could be resolved by mid-year, which could permit "back-to-back" filings in melanoma and cervical cancer later this year. Our Take: One of our favorites, IOVA just closed at a new high. This is a high risk / reward biotech stock, but the potential here is huge. There are also good options here to trade with. This one can be used for both short term trading and a longer term healthcare holding. Selling puts and / or buy-writes will work with this one. $IOVA, Iovance Biotherapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .